{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-019900","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.766653+00:00","generated_at":"2026-05-18T06:12:45.945645+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise","bullets":["Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.","Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).","Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.","CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-019900","json":"https://secwatch.observer/filing/0001641172-25-019900.json","markdown":"https://secwatch.observer/filing/0001641172-25-019900.md","text":"https://secwatch.observer/filing/0001641172-25-019900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/0001641172-25-019900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:12:45.945645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}